Ligand Pharmaceuticals Inc. LGND reported third-quarter 2017 adjusted earnings of ... Ligand’s shares have outperformed the industry year to date. The stock has soared 42.5% compared with the industry’s 2.7% increase. View photos Total …
When we were bullish on the stock upon our launch in Dec-2014, it appeared to us that the Street was not paying fully for the existing or future streams, and investors were generally unfamiliar with the LGND story." For an analyst ratings …
Investors who purchased shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) have certain options and for certain …
Ligand Pharmaceuticals Incorporated LGND inked a deal to acquire Crystal Bioscience, Inc. for $25 million in cash ... Consequently, Ligands shares have outperformed the industry year to date. The stock has surged 36.4% compared …
Ligand Pharmaceuticals Incorporated LGND is scheduled to report second-quarter 2016 results on Aug 4 before the market opens. In the last reported quarter, Ligand had posted a positive earnings surprise of 67.39%. Let’s see how things are …
A month has gone by since the last earnings report for Ligand Pharmaceuticals Incorporated LGND. Shares have added about 5.1% in that time frame, outperforming the market. Will the recent positive trend continue leading up to the …
Ligand Pharmaceuticals Inc. LGND reported third-quarter 2017 adjusted earnings of ... Ligand’s shares have outperformed the industry year to date. The stock has soared 42.5% compared with the industry’s 2.7% increase. View photos Total …